Jane Street’s LB Pharmaceuticals LBRX Stock Holding History

Jane Street’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,733	Closed	-$706K	–	13576
2025 Q4	$706K	Buy	31,733 +1,388	+5%	+$24.2K	﹤0.01%	6937
2025 Q3	$479K	Buy	+30,345	New	+$481K	﹤0.01%	7966

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jane Street's LBRX Position: Q1 2026 in Review

Jane Street sold out of LB Pharmaceuticals (LBRX) in Q1 2026, closing a stake of 31,733 shares — an estimated $706K sold.

Jane Street first reported a position in LBRX in Q3 2025 and held it in 2 quarters. The position peaked at $706K in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Jane Street reported no remaining LB Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 31,733 LB Pharmaceuticals shares in Q1 2026, an estimated $706K.
Jane Street first reported a position in LB Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Jane Street's LB Pharmaceuticals position peaked at $706K in Q4 2025.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.